Thalidomide-associated thrombocytopenia

Annals of Pharmacotherapy

Volumn 39, Issue 11, 2005, Pages 1936-1939

  Duyvendak, Michiel ^a   Naunton, Mark ^a   Kingma, Bert J ^a   Brouwers, Jacobus R B J ^b  

^a Tjongerschans Hospital   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Multiple myeloma; Neutropenia; Thalidomide; Thrombocytopenia

Indexed keywords

ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; DEXAMETHASONE; MELPHALAN; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; QUININE; SULFONAMIDE; THALIDOMIDE;

AGED; ARTICLE; BLOOD TOXICITY; CASE REPORT; DYSPNEA; EDEMA; FEBRILE NEUTROPENIA; FEMALE; FLU LIKE SYNDROME; HEMATOMA; HUMAN; MULTIPLE MYELOMA; NEUTROPENIA; PERIPHERAL EDEMA; PETECHIA; PRIORITY JOURNAL; PROBABILITY; RASH; SYMPTOMATOLOGY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; XEROSTOMIA;

ADMINISTRATION, ORAL; AGED; DEXAMETHASONE; FEMALE; HUMANS; MELPHALAN; MULTIPLE MYELOMA; NEUTROPENIA; PREDNISOLONE; THALIDOMIDE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 27344450706     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G256     Document Type: Article

References (16)

1. Weber D. Thalidomide and its derivatives: new promise for multiple myeloma. Cancer Control 2003;10:375-83.
2. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med 1994;330:484-9.
3. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71.
4. Mileshkin L, Biagi JJ, Mitchell P, Underhill C, Grigg A, Bell R, et al. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 2003;102:69-77.
5. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001;98:492-4.
6. Dimopoulos MA, Eleutherakis-Papaiakovou V. Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 2004;117:508-15.
7. van den Berg WN, Eliel MR, Battermann JJ. Tumor-specific guidelines. In: Oncology book part 1. Utrecht: Cancer Institute Netherlands, 2002:472-8.
8. Duval M, Rohrlich P, Thomas E, Fenneteau O, Nafa S, Schlegel N, et al. Three cases of neutropenia and thrombopenia attributable to thalidomide in the treatment of GVHD (abstract). Bone Marrow Transplant 1995;15(suppl 2):147.
9. Hattori Y, Kakimoto T, Okamoto S, Sato N, Ikeda Y. Thalidomide-induced severe neutropenia during treatment of multiple myeloma. Int J Hematol 2004;79:283-8.
10. Curley MJ, Hussein SA, Hassoun PM. Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma. J Clin Microbiol 2002;40:2302-4.
11. Okikawa Y, Takimoto Y, Noda M, Imagawa J, Katayama Y, Sakai A, et al. [Single-agent thalidomide for advanced and refractory multiple myeloma] Japanese. Rinsho Ketsueki 2003;44:368-74.
12. Hattori Y, Iguchi T. Thalidomide for the treatment of multiple myeloma. Congenit Anom (Kyoto) 2004;44:125-36.
13. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
14. Garg SK, Sarker CR. Aspirin-induced thrombocytopenia on an immune basis. Am J Med Sci 1974;267:129-32.
15. Groneberg DA, Barkhuizen A, Jeha T. Simvastatin-induced thrombocytopenia (letter). Am J Hematol 2001;67:277.
16. Aster RH. Drug-induced immune cytopenias. Toxicology 2005;209:149-53.